A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Germany- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Hohe Warte 8, Gruener Baum, 95445 Bayreuth, Germany
Klinikum Bayreuth GmbH in Bayreuth, Germany specialises in clinical trials of conditions such as Dementia Alzheimer's type, Breast cancer, Colorectal cancer metastatic, Relapsing multiple sclerosis, and other specialisations. This site conducts important research.
The Neurology department at Klinikum Bayreuth conducts research on neurodegenerative and inflammatory disorders of the central nervous system, seeking to advance treatment options for patients.
With four active studies and eight investigators, the site evaluates new therapies for cognitive decline and multiple sclerosis, aiming to improve safety, tolerability, and disease‑modifying outcomes.
Clinical trials currently enrolling participants at this site.
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
GermanyMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.